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Abstract 
Aims: The representativeness of the mandatory bacterial strains specified in 
European standards for in vitro assay of the bactericidal activity of antiseptics 
was evaluated by testing the activity of an antiseptic combining chlorhexidine 
digluconate 0.2% and benzalkonium chloride 0.5% against 21 additional bac-
terial strains, and the positive interaction between these two biocidal agents 
was assessed. Methods and Results: The bactericidal activity of the antiseptic 
solution used pure or diluted was assessed according to the European stan-
dards EN 1040 and EN 13727. The contact time was 1 min at 20˚C. Interfer-
ing substances used in the EN 13727 assay were bovine serum albumin and 
sheep erythrocytes, simulating “dirty” conditions, and hard water. A reduc-
tion of colony-forming units by ≥5 log10 was deemed to meet the require-
ments to conclude bactericidal activity. Under “basic” conditions, the bacteri-
cidal activity of the antiseptic was observed against all four mandatory strains 
specified in the standards as well as against nearly all the additional strains 
tested, including most of those with acquired antibiotic-resistance. The posi-
tive interaction between the two biocidal agents was also confirmed. Under 
“dirty” conditions, the bactericidal activity of the antiseptic solution was 
maintained against all the mandatory strains and was reduced against only 
four of the additional strains tested. Conclusions: With regard to the antisep-
tic tested and under the experimental conditions described, bactericidal activ-
ity evidenced against the mandatory strains appeared to be representative of 
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that manifested against a wide range of the main pathogenic bacteria. Re-
duced bacterial activity against some of the additional strains tested (e.g. En-
terobacteriaceae) was observed under “dirty” conditions. Significance and 
Impact of the Study: EN 13727 with some experimental adjustments 
represents an additional appropriate standard that needs to be considered for 
mucocutaneous antiseptic assessment. However, it may be worth including 
other specific bacterial strains to those specified in the standard, when eva-
luating antiseptics intended for use in certain clinical situations.  
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1. Introduction 
Over the past decade, antiseptics have been increasingly used for prophylactic or 
therapeutic purposes, notably as a result of the continuing rise in the frequency 
of antibiotic resistance in the healthcare setting [1]. When used appropriately, 
antiseptics can decrease cutaneous or mucosal microbial colonization by reduc-
ing both transient and commensal flora [2], and their clinical benefit in control-
ling infection is well established.  
Many antiseptic formulations including active substances such as chlorhex-
idine, iodine or chlorine derivatives, or quaternary ammonium compounds 
(QACs), are currently available. The choice of an antiseptic and the optimal 
conditions of its use should be guided by its known antimicrobial spectrum, the 
targeted situations or indications (e.g. pre-procedural antisepsis, antiseptic 
treatment of skin, wounds or mucous membranes) and the potential risks of ad-
verse effects related to each ingredient and to the formulation as a whole. Some 
mucocutaneous antiseptic agents, such as chlorhexidine or iodine derivatives, 
may have a broad spectrum of activity against the main bacteria, whereas others, 
like QACs, may kill a smaller range of disease-causing organisms depending on 
their membrane structure (Gram-positive or Gram-negative) [3]. 
The spectrum of bactericidal activity of antiseptics is primarily determined 
using in vitro tests carried out according to internationally accepted standards 
and generally consisting in determination of the reduction in the number of via-
ble test microorganisms by pure or diluted solutions of the antiseptic. The me-
thodology used in this study conforms to that described in European (EN) stan-
dards. The standard EN 14885 [4] describes the application of European stan-
dards to chemical disinfectants and antiseptics and more specifically indicates 
the recommended and/or mandatory assays for active substances and newly 
marketed products: basic in vitro bactericidal activity (phase 1), in vitro activity 
under the conditions of intended use (phase 2, step 1), in vivo activity after 
standardized bacterial inoculation on skin (phase 2 step 2) and in vivo activity 
S. Salvatico et al. 
 
 
DOI: 10.4236/ojmm.2018.83006 58 Open Journal of Medical Microbiology 
 
under conditions of practical use in humans (phase 3).  
The standard EN 1040 [5] implemented in April 2006 and never updated 
since then, describes the phase 1 assay recommended to test the basic bactericid-
al activity of an active antiseptic substance or a formulated product under de-
velopment. This assay may also be used, for instance, to assess potential interac-
tion(s) between active substances or excipients. Bactericidal activity is deter-
mined against Pseudomonas aeruginosa ATCC 15442 and Staphylococcus au-
reus ATCC 6538, after a 5-minute contact time at 20˚C, in the absence of any 
organic contaminant.  
The standard EN 13727 [6] is a phase 2 step 1 standard, describing the assay 
required for the in vitro bactericidal assessment of final, market-ready formula-
tions of hand hygiene products. The aim of this assay is to establish the bacteri-
cidal activity of the product under simulated practical conditions relevant to its 
intended use (e.g. at dilutions and time points corresponding to the actual pat-
terns of use of the final antiseptic preparation).  
Although phase 2 standards for assay of the bactericidal activity of hygienic 
and surgical hand washes and hand rubs are well described in EN 14885 [4], 
there is currently no phase 2 standard that specifically addresses evaluation of 
the bactericidal activity of mucocutaneous antiseptics in other simulated condi-
tions of use. Yet the presence of many organic (proteins) or inorganic (electro-
lytes, divalent cations) substances found in biological fluids, such as blood, ex-
udates or pus, decreases or even completely inhibits the in vitro bactericidal ac-
tivities of numerous marketed antiseptic solutions and individual active sub-
stances [2] [7] [8] [9]. These decreases in bactericidal activity have also been ob-
served in vivo [7] [10] [11] [12] [13] [14].  
The assay described in the standard EN 13727 [6] has already been used to as-
sess the bactericidal activity of mucocutaneous antiseptics in the presence of in-
terfering substances, i.e. under conditions resembling as closely as possible those 
pertaining to their routine use in medical practice [15]. 
Two kinds of interfering substances are specified in this standard: a mixture of 
bovine albumin and erythrocytes for “dirty” conditions, or bovine albumin alone 
for “clean” conditions. The current version of EN 13727 [6] requires the use of 
four different test organisms: two Gram-positive cocci: Staphylococcus aureus 
ATCC 6538 and Enterococcus hirae ATCC 10541, and two Gram-negative bacil-
li: Escherichia coli K12 NCTC 10538 and Pseudomonas aeruginosa ATCC 15442 
and stipulates specific contact times for hygienic or surgical hand washes and 
hand rubs.  
The strains specified in EN 13727 [6] and in EN 1040 [5] are deemed to be 
representative of the most clinically relevant bacteria found in health care set-
tings, in terms of spectrum and pathophysiological involvement [16] [17]. 
Hence, E. coli, P. aeruginosa, S. aureus and Enterococci are the leading patho-
gens responsible for the majority of nosocomial infections [17] [18]. However, 
the bacteriology of the commonly isolated (nosocomial) pathogens has changed 
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over time. For example, Proteus spp., Klebsiella spp. and Escherichia spp. were 
responsible for nosocomial infections in the 1960s, while recent surveys have in-
dicated that streptococci, along with coagulase-negative and coagulase-positive 
staphylococci, have re-emerged, whereas the incidence of K. pneumoniae and E. 
coli has declined [17]. Consequently, with the development of new emergent and 
sometimes challenging nosocomial pathogens and in the currently evolving 
context of bacterial resistance to antimicrobials, it is worth questioning whether 
the bactericidal activity of an antiseptic formulation against the four mandatory 
strains stipulated in European standards may truly predict their effectiveness 
against normal flora and cutaneous pathogens. Although corresponding to the 
species responsible for the majority of nosocomial infections, these reference 
strains therefore represent only a subset of the bacteria of concern. It is worth 
noting that in the USA, time-kill tests, based on a principle similar to that of the 
European suspension tests, must be performed against 23 laboratory strains con-
sidered to be representative of nosocomial pathogens [19].  
With the aim of investigating the representativeness of the assay conditions 
imposed by European standards, we tested a marketed antiseptic solution com-
bining chlorhexidine digluconate (CHX) 0.2% and benzalkonium chloride 
(BZK) 0.5% (Dermobacter®, Laboratoire Innotech International) previously con-
firmed to be bactericidal according to the standard NF EN 13727 [15] and 
commonly used for injured skin and superficial wound antisepsis. Our objec-
tives were to address the following questions:  
1) Is the bactericidal activity of this tested antiseptic preserved under “dirty” 
conditions and after a short contact time against both the mandatory and other 
relevant bacterial strains?  
2) Do assays employing the two test strains stipulated in EN 1040 [5] and the 
four test strains specified in EN 13727 [6] provide sufficient evidence of the 
comprehensive bactericidal activity of this antiseptic?  
We therefore investigated the in vitro spectrum of antibacterial activity 
against the mandatory test strains stipulated in the European standards EN 1040 
[5] and EN 13727 [6] as well as against 21 other pathogens of concern in health 
care settings including antibiotic-resistant strains (such as methicillin-resistant 
Staphylococcus species or vancomycin-resistant Enterococcus species) and other 
bacteria with pathogenic potential for the skin or mucosa. Finally, the known 
positive interaction between the two active substances included in this antiseptic 
preparation was checked. 
2. Materials and Methods 
2.1. Solutions 
The antiseptic solutions tested are described below: 
- BZK 0.5% (w/v) solution (Laboratoire Innotech International, batch 
DER-1303-007), 
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- CHX 0.2% (w/v) solution (Laboratoire Innotech International, batch 
DER-1303-008), 
- CHX 0.2% + BZK 0.5% solution (Laboratoire Innotech International, batch 
DER-1303-009), 
- Dermobacter®, solution for cutaneous application combining CHX 0.2% and 
BZK 0.5% (Laboratoire Innotech International, batch CH106). This licensed 
antiseptic is a foaming solution indicated for the cleansing and adjuvant 
treatment of skin and mucous membrane disorders, either primarily of bac-
terial origin or susceptible to bacterial superinfection. In practice, the solu-
tion is used pure on skin and diluted 1:10 on mucous membranes, intensive 
rinsing being required following the application. Excipients comprise coco 
alkyl dimethyl betaines, ethylene oxide and propylene oxide copolymers, hy-
droxyethylcellulose, monohydrated citric acid and sodium citrate. 
2.2. Bacterial Strains 
The bacterial strains stipulated by the standards EN 1040 [5] and/or EN 13727 
[6] for bactericidal assay were used, namely S. aureus CIP 4.83 (ATCC 6538), P. 
aeruginosa CIP 103467 (ATCC 15442), E. coli CIP 54117 (NCTC 10538) and E. 
hirae CIP 58.55 (ATCC 10541). These strains were provided by the Pasteur In-
stitute Collection (Paris, France). Receipt strains were treated as recommended 
by Pasteur Institute Collection and then stored at −80˚C in a glycerol-based 
cryoprotective solution to be in compliance with the standard NF EN 12353. A 
further 21 strains were also tested, giving a total of 25 bacterial strains. These 
additional strains included both referenced strains (from the Pasteur Institute 
Collection [CPI]; or the American Type Culture Collection [ATCC]) and clinical 
isolates (from the University Hospital, Toulouse, France), corresponding to the 
species most commonly involved in cutaneous and/or mucosal infections. The 
distribution between Gram-positive and Gram-negative bacteria was as follows:   
- Gram-positive strains: 
Aerobes and aerotolerants: Staphylococcus epidermidis CIP 6821, Strepto-
coccus pyogenes CIP 5641T, Streptococcus agalactiae CIP 106884, Corynebacte-
rium amycolatum CIP 403452T and strains expressing acquired resistance: Sta-
phylococcus aureus MRSA ATCC 33591, Staphylococcus aureus VISA CIP 
106757 and Enterococcus faecium VanA CIP 107387;  
Anaerobes/microaerophiles/capnophiles including: Propionibacterium acnes 
CIP 53117T, Clostridium perfringens CIP 103409, Finegoldia magna CIP 
103666, Gardnerella vaginalis CIP 7074T. 
- Gram-negative strains: 
Aerobes and aerotolerants: Klebsiella pneumoniae CIP 8291, Enterobacter 
cloacae CIP 6058T, Serratia marcescens CIP 103716, Proteus mirabilis CIP 
103181T, Citrobacter freundii CIP 57.32T, Acinetobacter baumanii CIP 70.34T 
and strains expressing acquired resistance: ESBL-producing Klebsiella pneumo-
niae CTXM15 (clinical isolate), Stenotrophomonas maltophilia tono R (clinical 
isolate);  
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Anaerobes/microaerophiles/capnophiles: Bacteroides fragilis AIP 7716, 
Neisseria gonorrhoeae CIP 7918T. 
Cultures were maintained and colony-forming units (CFU) were counted on: 
Tryptone soy agar (Biomérieux, Crapone, France; casein peptone 15.0 g, soy 
peptone 5.0 g, sodium chloride (NaCl) 5.0 g, agar 15.0 g, and water to 1 L) for 
the main aerobes and facultative anaerobes; Columbia agar (Biomérieux, Cra-
pone, France; meat and casein peptone 10.0 g, hydrolyzed animal protein 10.0 g, 
heart peptone 3.0 g, corn starch 1.0 g, NaCl 5.0 g, agar 13.5 g, and water to 1 L) 
for Corynebacterium amycolatum CIP 403452T (after the addition of 10% neu-
tralizer for CFU counts); Columbia agar + 5% sheep erythrocytes (Biomérieux; 
Crapone, France; meat and casein peptone 10.0 g, hydrolyzed animal protein 
10.0 g, heart peptone 3.0 g, corn starch 1.0 g, NaCl 5.0 g, agar 13.5 g, sheep blood 
15 ml, and water to 1 L) for Gardnerella vaginalis CIP 7074T, under anaerobic 
conditions for Propionibacterium acnes CIP 53117T, Clostridium perfringens 
CIP 103409, Finegoldia magna CIP 103666 and Bacteroides fragilis AIP 7716;  
Chocolate PolyViteXagar (Biomérieux, Crapone, France; casein peptone 7.5 g, 
meat peptone 7.5 g, corn starch 1.0 g, dipotassium phosphate 4.0 g, NaCl 5.0 g, 
hemoglobin bovine 10.0 g, agar 10.0 g, PolyViteX 10 mL, and water to 1 L) un-
der 5% CO2 for Neisseria gonorrhoeae CIP 7918T; and Tryptone soy agar under 
5% CO2 for Streptococcus agalactiae CIP 106884 and under aerobiosis for the 
other strains with the addition of 10% neutralizer for Streptococcus pyogenes 
CIP 5641T (incubation 36˚C ± 1˚C – 24 to 48 h).  
2.3. Trial Protocols 
1) Evaluation of the Bactericidal Spectrum and Sensitivity to Interfering Sub-
stances  
Bactericidal activity against S. aureus CIP 4.83, P. aeruginosa CIP 103467, and 
23 additional strains was tested according to protocol described in EN 1040 
(Table 1) [5]. Bacterial suspensions were prepared in tryptone salt at concentra-
tions ranging from 1.5 × 108 to 5.0 × 108 CFU mL−1, with final test concentra-
tions ranging between 1.5 × 107 and 5.0 × 107 CFU mL−1. The tested antiseptic 
was diluted in water for injectable preparations (to concentrations of 80%, 50% 
and 10% v/v). Preliminary assays were performed to define the range of dilu-
tions allowing discrimination of differences in antibacterial activity. The tests 
were conducted according to standard conditions (5 min ± 10 s contact duration 
at a temperature of 20˚C ± 1˚C) and for an additional contact time of 1 min ± 5 
s, to allow comparison with the results obtained using the protocol described in 
EN 13727 [6].  
The experimental conditions specified in EN 13727 [6] for hygienic and sur-
gical hand rubs and washes were if necessary adapted according to the condi-
tions of use of the tested antiseptic in its various indications. In particular, cer-
tain indications require dilution of the antiseptic prior to use. Notably, for use 
specifically on the vaginal mucosa (against Neisseria gonorrhoeae, Gardnerella 
vaginalis) and on wounds (against Clostridium perfringens), the product 
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Table 1. Assay conditions adapted from the European standards EN 1040 and EN 13727. 
 
EN 1040 EN 13727 
Basic conditions Representative use conditions 
Mandatory strains S. aureus P. aeruginosa 
S. aureus 
P. aeruginosa 
E. coli 
E. hirae 
Additional strains* 12 Gram+ 11 Gram− 
11 Gram+ 
10 Gram− 
Composition of  
the tested antiseptic 
Foaming solution including 0.2% benzalkonium chloride (CBK)  
and 0.5% chlorhexidine digluconate (CHX) (Dermobacter®) 
Concentrations of the  
antiseptic solution tested Pure (97%/80%) or diluted (10%) 
Interfering substances - Sheep erythrocytes (3 mL∙L
−1) + 
bovine serum albumin (3 g∙L−1) 
Contact time/T˚ 1 min at 20˚C 
Bactericidal activity:  
log reduction required ≥ 5 
*Strains commonly involved in mucocutaneous infections including some with acquired resistance to anti-
biotics (MRSA, ESBL-producing Klebsiella pneumoniae, VRE). ESBL: extended-spectrum β-lactamase; 
MRSA: methicillin-resistant Staphylococcus aureus; VRE: vancomycin-resistant Enterococcus species. Two 
vaginal strains tested only after dilution according to EN 13727. 
 
is always diluted. The highest recommended concentrations of 97% or 80% (v/v) 
were employed for the ready-to-use product, 50% or 10% (v/v) concentrations 
being employed to reflect use of the diluted product. The theoretically inactive 
concentration tested was 1% for the four mandatory bacterial strains stipulated 
in the European standard and 0.1% for the additional strains.  
The most restrictive assay conditions were selected, i.e. dilutions in hard water 
(recommended for the application of diluted solutions) and contact under “dirty 
conditions” (recommended to simulate antiseptic use without previous cleaning 
of the application zone). Hard water is a saline solution including magnesium 
chloride, calcium chloride, sodium bicarbonate, that simulates tap water, with a 
hardness of 30˚F (equivalent to 21 English degrees). Divalent cations play a con-
siderable role in antiseptic activity and are therefore considered as potentially 
interfering substances [2] [7] [8] [9]. For “dirty conditions”, the interfering sub-
stances comprised a mixture of 3 g∙L−1 bovine serum albumin (Sigma Aldrich, 
Saint-Quentin Fallavier, France) and 3 mL∙L−1 of sheep erythrocytes (Bi-
omérieux, Crapone, France).  
Assays were performed at a temperature of 20˚C ± 1˚C and with a contact dura-
tion of 1 min ± 5 s, more restrictive than the maximum contact time of 5 min sti-
pulated in the standard for surgical hand rubs and washes. 
The absence of any toxic effect of the experimental conditions and the neutra-
lizer (or filtration procedure), as well as the validation of the dilution neutraliza-
tion step was checked as specified in the standards EN 1040 and EN 13727 [5] 
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[6]. The neutralizer used in the assays comprised Tween 80 (10%), saponin 
(2%), lecithin (2%), sodium thiosulfate (0.5%) (Sigma Aldrich), and Trypcase 
soy broth (Biomérieux). Filtration rather than neutralization was used for 
assays of bactericidal activity against G. vaginalis (nitrocellulose membrane 
0.45 µm—Millipore—rinsing solution: sterile distilled water 2 × 100 mL), and N. 
gonorrhoeae (Durapore hydrophobe membrane 0.45 µm—Millipore—rinsing 
solution: sterile distilled water 2 × 100 mL).  
After neutralization or filtration, residual viable bacteria (CFU) were counted 
after incubation in the appropriate agar for the control and the test suspensions. 
The CFU counts recorded at this time, expressed in decimal logarithms (log10 
values) were subtracted from the basal values determined prior to antiseptic ex-
posure in order to calculate the log reductions in CFU count. The upper limit of 
the CFU count indicating bactericidal activity, as defined by the standard, cor-
responds to a lower limit in terms of log reduction (expressed as <3 in the results 
tables). The lower limit of the CFU count defined by the standard induces an 
upper limit in terms of log reduction (≥5 in the results tables). The tested anti-
septic solution is considered bactericidal according to EN 1040 [5] at concentra-
tions reducing the initial bacterial count by ≥5 log. According to EN 13727 [6], 
the tested antiseptic solution is considered bactericidal for hygienic and surgical 
hand rubs if, when used undiluted, it produces a ≥5 log reduction in CFU 
counts; and for hygienic hand washes or for surgical hand washes if, when used 
diluted (≤50%), it produces a ≥5 log or ≥3 log reduction respectively. In this 
study, bactericidal activity against specific microorganisms was considered to be 
evidenced when a ≥5 log reduction in CFU counts was observed in assays per-
formed according to EN 1040 requirements and based on the most restrictive 
acceptance criteria for hand hygienic friction (NF EN 13727) [5] [6]. 
2) Assessment of CHX-BZK Interaction 
The test conditions stipulated in EN 1040 [5] were applied to confirm the pos-
itive interactions between CHX and BZK activities when combined such as in 
the tested licensed antiseptic. The bactericidal activities of CHX 0.2% (w/v) and 
BZK 0.5% (w/v) separately, of the combination CHX - BZK, and of the licensed 
antiseptic Dermobacter® were tested against Staphylococcus aureus CIP 4.83 and 
Pseudomonas aeruginosa CIP 103467 at the concentrations and ratio present in 
Dermobacter® and the results compared. Bacterial suspensions and dilutions of 
each antiseptic preparation were made as described above. Assays were con-
ducted according to the standard, at a temperature of 20˚C ± 1˚C and with a 
contact time of 5 min ± 10 s.  
3. Results 
3.1. Spectrum of Bactericidal Activity and Sensitivity to  
Interfering Substances  
As shown in Table 2, the bactericidal activity of Dermobacter® observed after 
1 minute of contact and in the absence of any interfering substance (EN 1040  
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Table 2. Bactericidal activity of Dermobacter® under basic conditions according to the 
standard EN 1040 (contact time: 1 min). 
 
Concentration (v/v) 
80% 50% 10% 
Mandatory strains 
Staphylococcus aureus CIP 4.83    
Pseudomonas aeruginosa CIP 103467    
Additional Gram + strains 
Enterococcus hirae CIP 58.55    
Staphylococcus epidermidis CIP 6821    
Streptococcus pyogenes CIP 5641T    
Streptococcus agalactiae CIP 106884    
Corynebacterium amycolatum CIP 103452T    
Propionibacterium acnes CIP 53117T    
Clostridium perfringens CIP 103409    
Finegoldia magna CIP 103666    
Gardnerella vaginalis CIP 7074T    
Additional Gram + strains with acquired antibiotic resistance 
Staphylococcus aureus MRSA ATCC 33591    
Staphylococcus aureus VISA CIP 106757    
Enterococcus faecium VAN A CIP 107387    
Additional Gram—strains 
Escherichia coli CIP 54.117    
Klebsiella pneumoniae IP 8291    
Enterobacter cloacae CIP 6058T    
Serratia marcescens CIP 103716    
Acinetobacter baumannii CIP 70.34T    
Citrobacter freundii CIP 57.32T    
Proteus mirabilis CIP 103181T    
Bacteroides fragilis AIP 7716    
Neisseria gonorrhoeae CIP 7918T    
Additional Gram—strains with acquired antibiotic resistance 
ESBL-producing Klebsiella pneumoniae CTXM15    
Stenotrophomonas maltophilia tonoR    
 
 Log reduction < 3 
 3 ≤  Log reduction < 5 
 Log reduction ≥ 5 
The theoretically inactive concentration tested was 0.1% (data not shown). Bactericidal activity is expressed 
as a logarithmic reduction at the tested concentrations 80%, 50% and 10%. 
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protocol, [5]) was demonstrated against both Gram-positive and Gram-negative 
bacteria, including anaerobes and microaerophiles and, above all, against strains 
expressing acquired antibiotic resistance (log reduction in CFU count ≥ 5). Un-
der these experimental conditions, the bactericidal activity of the antiseptic was 
sustained even when diluted to 10% (v/v). The only concentration bactericidal 
against Proteus mirabilis was 10% (v/v), the log reduction in CFU count noted 
for this strain at the higher concentrations being under 5 (4.59 at 80% with a 
contact time of 5 min, and 4.53 at 50% with a contact time of 1 min).  
Under drastic conditions, including dilution of the product in hard water and 
“dirty” conditions (as specified in EN 13727 [6]), the bactericidal activity of 
Dermobacter® was for the most part preserved, even after a short (1 min) contact 
time (Table 3). At the 10% concentration, the antiseptic achieved a log reduc-
tion in CFU count ≥ 5 on 22 out of 25 strains and a log reduction ≥ 3 but <5 on 
23 out of 25 strains. Its bactericidal activity was nevertheless reduced under these 
conditions against C. perfringens CIP 103409 (50%: 4.29 log and 10%: 4.19 log), 
S. marcescens CIP 103716 (80%: 3.39 log, 50%: 4.38 log, 10%: 2.36 log) and 
ESBL-producing K. pneumoniae CTXM15 (80%: 4.32 log), although a ≥3 log 
decrease in CFU counts was still achieved.  
3.2. CHX—BZK Interaction and Final Formulation Validation 
According to preliminary assays on the CHX 0.2% - BZK 0.5% combination, 
demonstrating bactericidal activity at a dilution of 0.5% and loss of activity at a 
dilution of 0.1% (data not shown), the concentrations tested for the interaction 
assessment ranged from 0.1% to 0.6% (v/v). The mean logarithmic reductions in 
CFU count achieved against S. aureus CIP 4.83 and P. aeruginosa CIP 103467 
after a 5-min contact are presented in Table 4. 
The bactericidal activity of the CHX—BZK combination was higher than that 
of each active substance tested separately, confirming a positive interaction be-
tween the two antiseptic agents. The CHX—BZK combination showed bacteri-
cidal activity at concentrations of 0.2% against S. aureus and 0.5% against P. ae-
ruginosa, whereas these concentrations were inactive when the component anti-
septic agents were tested individually (Table 4). 
The licensed antiseptic solution Dermobacter® manifested a bactericidal activ-
ity similar to that of the CHX—BZK solution, indicating no negative interaction 
with the excipients present in the formulation. 
4. Discussion 
The current requirement to establish that active substances or products under 
development, whatever their specific areas of application, have bactericidal ac-
tivity is EN 1040 [5], a phase 1quantitative suspension test. However, this phase 
1 test is insufficient to claim bactericidal activity in any particular clinical indica-
tion. To establish that a product has bactericidal activity under the practical 
conditions representative of its intended use, phase 2, step 1 quantitative  
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Table 3. Bactericidal activity of Dermobacter® under “dirty” conditions according to the 
standard EN 13727 (contact time: 1 min). 
 
Concentration (v/v) 
97%/80% 50% 10% 
Mandatory strains 
Staphylococcus aureus CIP 4.83    
Pseudomonas aeruginosa CIP 103467    
Escherichia coli CIP 54.117    
Enterococcus hirae CIP 58.55    
Additional Gram + strains 
Staphylococcus epidermidis CIP 6821    
Streptococcus pyogenes CIP 5641T    
Streptococcus agalactiae CIP 106884    
Corynebacterium amycolatum CIP 103452T    
Propionibacterium acnes CIP 53117T    
Clostridium perfringens CIP 103409 ND   
Finegoldia magna CIP 103666    
Gardnerella vaginalis CIP 7074T ND   
Additional Gram + strains with acquired antibiotic resistance 
Staphylococcus aureus MRSA ATCC 33591    
Staphylococcus aureus VISA CIP 106757    
Enterococcus faecium VAN A CIP 107387    
Additional Gram - strains 
Klebsiella pneumonia CIP 8291    
Enterobacter cloacae CIP 6058T    
Serratia marcescens CIP 103716    
Acinetobacter baumannii CIP 70.34T    
Citrobacter freundii CIP 57.32T    
Proteus mirabilis CIP 103181T    
Bacteroides fragilis AIP 7716    
Neisseria gonorrhoeae CIP 7918T ND   
Additional Gram - strains with acquired antibiotic resistance 
ESBL-producing Klebsiella pneumoniae CTXM15    
Stenotrophomonas maltophilia tonoR    
 
 Log reduction < 3 
 3 ≤ Log reduction < 5 
 Log reduction ≥ 5 
ND Not determined 
The theoretically inactive concentration tested was 1% or 0.1% (for the mandatory strains and for the addi-
tional strains, respectively; data not shown). Bactericidal activity is expressed as a logarithmic reduction at 
the tested concentrations 97%/80% (97% for the mandatory strains, 80% for the additional strains with the 
exception of S. marcescens, P. mirabilis and C. perfringens for which both concentrations were tested), 
50%, and 10%. 
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Table 4. Bactericidal activity of chlorhexidine digluconate (CHX), benzalkonium chloride 
(BZK), the CHX-BZK combination* and the licensed antiseptic Dermobacter® against S. 
aureus CIP 4.83 and P. aeruginosa CIP 103467 according to the standard EN 1040. 
S. aureus CIP 4.83 
Concentration 
0.6% 0.5% 0.4% 0.3% 0.2% 0.1% 
BZK 0.5% ND      
CHX 0.2% ND      
BZK 0.5% + CHX 0.2%* ND    +  
Dermobacter® ND ND   +  
 
P. aeruginosa CIP 103467 
Concentration 
0.6% 0.5% 0.4% 0.3% 0.2% 0.1% 
BZK 0.5%       
CHX 0.2%       
BZK 0.5% + CHX 0.2%*  +     
Dermobacter®  +     
 
 3 ≤ Log reduction < 5 
 Log reduction ≥ 5 
ND Not determined 
+: concentrations demonstrating a positive interaction between BZK and CHX.  
*BZK 0.5% + CHX 0.2 % corresponding to the same combination of active substances as in Dermobacter®, 
without the excipients found in this commercial preparation. 
 
suspension tests are required, such as those stipulated in the standard EN 13727, 
applicable to antiseptic products intended for hygienic or surgical hand rubs and 
washes [6].  
Both these standards specify the use of mandatory bacterial strains including 
Gram-positive cocci belonging to the most important groups (S. aureus and E. 
hirae), and the main representatives of Gram-negative bacilli (E. coli among the 
Enterobacteriaceae and P. aeruginosa). However, many other bacteria may be 
involved in infections and consequently need to be controlled by the use of anti-
septics. For this reason, extended assays of bactericidal activity were performed 
on a licensed antiseptic (Dermobacter®, containing the active substances CHX 
0.2% and BZK 0.5%) to validate its bactericidal activity against the four manda-
tory strains stipulated by the relevant European standards, in comparison to that 
manifested against a further 21 bacterial pathogens implicated in various muco-
cutaneous infections, some of them presenting acquired resistance to antibiotics.  
First, the basic spectrum of bactericidal activity of the antiseptic was deter-
mined against a wide range of bacterial strains after 1 min of contact (at 20˚C) 
versus 5 min as recommended in the EN 1040 standard [5]. Under these defined 
conditions, the acceptance criterion for a log reduction in CFU count ≥ 5 was 
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met for the two mandatory strains and for 22/23 of the additional strains tested, 
whatever the concentrations used for the assays. The exception was Proteus mi-
rabilis, against which only a ≥3 to <5 log reduction in CFU counts was observed 
at the highest concentrations (80% and 50%).  
In a second step, assays were performed under more drastic conditions, i.e. 
with dilution in hard water and in the presence of interfering substances corres-
ponding to “dirty” conditions as defined in EN 13727 [6]. These assays similarly 
employed a contact time with the antiseptic of 1 min at 20˚C, and evaluated 
bactericidal activity against the four mandatory strains stipulated in EN 13727 
and 21 additional strains. In this standard, a 5 log reduction and a 3 log reduc-
tion are required for hygienic hand-rub (highest tested concentrations: 
97%/80%) and hand-wash (highest tested concentration: 50%), respectively. The 
bactericidal activity of Dermobacter® under these conditions was maintained 
against the majority of the bacterial strains tested. However, no bactericidal ac-
tivity against Proteus mirabilis was noted whatever the antiseptic concentration 
tested, and a decrease in the log reduction in CFU counts (from ≥5 to ≥3 under 
basic conditions to <5) against C. perfringens was detected at all antiseptic con-
centrations tested. Against S. marcescens, the antiseptic exhibited a ≥ 3 to <5 log 
reduction in CFU counts at concentrations of 80% and 50%, while the 10% con-
centration was inactive (log reduction < 3). Against ESBL-producing K. pneu-
moniae CTXM15, the log reduction was decreased to ≥3 to <5 at the 80% con-
centration but a ≥5 log reduction was preserved at the 50% and 10% concentra-
tions. Such a decrease in bactericidal activity at high concentrations has already 
been described with other antiseptics. In particular, the presence of certain exci-
pients, particularly detergents, has been postulated to effect bactericidal activity 
depending on their concentrations [15] [20]. The coco alkyl dimethyl betaines 
contained in Dermobacter® have known detergent properties that may affect the 
bactericidal efficacy of this product against certain specific bacterial strains. 
Comparison of the results obtained according to the two relevant European 
standards leads to the conclusion that 1) assays in which hard water is used to 
prepare dilutions of the antiseptic and that are conducted under “dirty” condi-
tions are more discriminating than phase 1 tests to validate the intended use of a 
licensed antiseptic, 2) the bactericidal activity of the antiseptic evaluated was 
preserved in the presence of interfering substances (including minerals, proteins 
and erythrocytes), against the mandatory strains stipulated in the standards, as 
well as against most of the additional strains tested, with nevertheless some ex-
ceptions. As antiseptics are used in routine medical practice on both “clean” and 
“dirty” skin wounds, and the presence of whole blood or white cells is known to 
decrease their bactericidal activity, it is worth questioning why antiseptics in-
tended for wound cleansing are still not required to meet standard criteria with 
interfering substances present. The draft revised version of EN 14485 currently 
under review does not envisage the use of “dirty” conditions for testing antisep-
tics. Consistently, in the very recently edited chapter of the European Pharma-
copoeia (2017 edition) concerning determination of the bactericidal, fungicidal 
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or yeasticidal activity of antiseptic medicinal products, the protocol described 
involves the use of only interfering substances corresponding to “clean” condi-
tions and a contact temperature of 33˚C [21]. Neither dilution of the product in 
hard water nor the use of “dirty” conditions is required. Moreover, the recom-
mended contact time (5 min for bacteria and 15 min for fungi) does not appear 
to match the actual conditions of use. 
Dermobacter® manifested a lower bactericidal activity against P. mirabilis than 
against the other bacterial strains tested, detected by the assay performed ac-
cording to EN 1040 and confirmed by the assay conducted as specified in EN 13727 
protocol. This finding was not surprising, given that P. mirabilis is considered as 
one of the species least susceptible to chlorhexidine among Gram-negative bacteria 
[22]. For three strains (two other Enterobacteriaceae and C. perfringens), a log 
reduction < 5 but ≥3 was noted in the EN 13727 assay, emphasizing that bacteri-
cidal activity persists and may be improved by a longer contact time. This is also 
suggested by the 5-fold log reduction in P. mirabilis counts reached after a 5-min 
contact time under the conditions stipulated in EN 1040 [5] (result not shown). 
It is worth noting that under “dirty” conditions, the bactericidal activity of Der-
mobacter® against the five tested strains with acquired antibiotic resistance me-
chanisms—and chosen because of their potential cross-resistance to antisep-
tics—was maintained at all dilutions, except against ESBL-producing K. pneu-
moniae CTXM15 at the highest concentration (log reduction in CFU counts ≥ 3 
but < 5). Nevertheless, the issue of cross-resistance between antibiotics and anti-
septics remains a matter of debate and controversy [23]. 
Finally, a previous study already underlined the value of adapting EN 13727 
conditions to validate antiseptics intended for cutaneous and mucosal uses [15]. 
In that study, the bactericidal activity of the licensed antiseptic Dermobacter® 
(containing 0.2% CHX and 0.5% BZK) against the mandatory strains was fully 
preserved under “dirty” conditions (log reduction > 5) unlike that of the other 
tested products containing respectively povidone-iodine (PVI) and a combina-
tion of hexamidine, chlorhexidine and chlorocresol.  
The results of our study confirm the choice of the mandatory strains stipu-
lated in EN 1040 and EN 13727 to validate an antiseptic formulation. However, 
adding certain other strains to those currently specified in the standard, such as 
those suggested here (P. mirabilis, C. perfringens and S. marcescens) could be of 
interest, depending on the intended clinical use of the antiseptic tested, although 
further experiments with other antiseptic agents would be needed to confirm 
their relevance. Antibiotic-resistant strains could also be added, even though in 
this study these strains did not appear to be less susceptible than the other bacte-
ria tested. 
The interactions between CHX and BZK and the impact of the excipients of 
the licensed antiseptic tested were also investigated in our study. With respect to 
bactericidal activity against S. aureus, the active concentration of the 0.2% CHX 
- 0.5% BZK combination was reduced by a third compared with those deter-
mined for CHX or BZK when tested separately. This positive interaction could 
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result from the known activity of the two agents on the cell wall of 
Gram-positive bacteria wall, enhancing disruption of bacterial membrane before 
interaction with intracellular proteins [24] [25] [26] [27]. Against P. aeruginosa, 
the bactericidal activity determined for CHX and BZK when tested individually 
was maintained when these compounds were assayed in combination. Our re-
sults therefore confirm that these two cationic agents are compatible, have no 
negative interactions, and may even interact positively against some microor-
ganisms.  
The licensed antiseptic tested exhibited a bactericidal activity similar to that of 
the combination of its two active substances alone (CHX 0.2% - BZK 0.5%). This 
result emphasizes that the excipients contained in the marketed formulation did 
not impair the bactericidal efficacy of these antiseptic agents against the tested 
strains. This is in line with the report published by Cowley et al. (2015), suggest-
ing that many formulated microbicides may even exhibit greater antibacterial 
potency than their unformulated active substances [28]. 
Resistance to antiseptics, including chlorhexidine [1] [22], but also QACs [29] 
[30], is becoming a challenge, particularly in the presence of interfering sub-
stances. This phenomenon leads to the selection of microbicide-resistant bacte-
ria. In this context, the results mentioned above stress the need for further inves-
tigations on antiseptic combinations. It may be hypothesized that the combina-
tion of active substances that act on similar or different targets on bacterial cells 
could be an interesting approach to limit or counteract the development of re-
sistance, notably by reducing their respective active concentrations and/or en-
larging their spectra of bactericidal activity. Benefits of such combinations have 
been reported, for instance, with respect to hydroalcoholic solutions of CHX and 
PVI [31] [32] [33]. Similarly, BZK has been shown to be a key factor for the pre-
servation of bactericidal activity of a CHX 0.2% - BZK 0.5% formulation in the 
presence of interfering substances, the activity of CHX 0.2% alone being inhi-
bited by 0.3% bovine albumin, whereas the combination CHX 0.2% - BZK 0.5% 
remained bactericidal [14].  
In conclusion, the licensed antiseptic tested (Dermobacter®; CHX 0.2% - BZK 
0.5%) exhibited a broad spectrum of bactericidal activity in vitro, including ac-
tivity against strains with acquired antibiotic resistance. Its bactericidal activity 
against the majority of the strains tested was unchanged under “dirty” condi-
tions and may be expected to remain unchanged in vivo, within its range of in-
dications concerning the prevention and treatment of cutaneous and mucosal 
infections. 
The results obtained with this licensed antiseptic support EN 14885 recom-
mendations regarding phase 2 standards for newly marketed products and indi-
cate that the mandatory strains stipulated in the standards EN 1040 [5] and EN 
13727 [6] are representative to assess the bactericidal activity of antiseptic. The 
1 min contact time and the presence of interfering substances appear to be the 
most appropriate testing conditions for mucocutaneous antiseptics. However, 
considering the decrease in the bactericidal activity of Dermobacter® against a 
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few strains observed under “dirty conditions”, attention should be paid by man-
ufacturers to the relevance of adding certain other strains to those stipulated in 
standards, according to the intended clinical use of the antiseptic to be tested, in 
order to avoid potential misuse. 
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